Robert C. Doebele

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 330: EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions.

  Cancer Research · 2026-04-03

• Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer

  Journal of Clinical Oncology · 2026-03-26

• Abstract A003: Adaptor sequestration and drug-induced potentiation of EGFR are widespread features of oncogenic RTK fusions

  Cancer Research · 2026-01-13

• Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i> –driven lung cancer by concurrent integrin and MET signaling

  Science Signaling · 2025-12-23 · 3 citations

• EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusionsPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-11-19 · 1 citations

• P3.12.71 Efficacy and Safety of Pralsetinib in Patients With Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data

  Journal of Thoracic Oncology · 2025-10-01

• Milademetan in Advanced Solid Tumors with <i>MDM2</i> Amplification and Wild-type <i>TP53</i>: Preclinical and Phase II Clinical Trial Results

  Clinical Cancer Research · 2025-08-11 · 9 citations

• Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

  Breast Cancer Research and Treatment · 2025-05-29 · 1 citations

• Efficacy and safety of pralsetinib in patients with advanced <i>RET</i> -fusion-positive NSCLC: Final data from the phase 1/2 ARROW study.

  Journal of Clinical Oncology · 2025-05-28 · 3 citations

• Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance

  Nature Communications · 2024-11-02 · 18 citations

• A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non–Small-Cell Lung Cancer

  Clinical Lung Cancer · 2024-09-01 · 2 citations

• Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i> -driven lung cancer via concurrent integrin and MET signalingPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2024-08-28 · 3 citations

• Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

  Nature Medicine · 2024-08-20 · 2 citations

• Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

  Journal of Clinical Oncology · 2024-07-19 · 57 citations